Myeloma-associated antigen-expressing cells

Myeloma-associated antigen-expressing cells refer to the malignant plasma cell population in multiple myeloma that expresses specific surface proteins used as therapeutic targets. These antigens, such as B-cell maturation antigen (BCMA) and GPRC5D, are highly overexpressed on the surface of cancerous plasma cells compared to normal tissues, providing a selective window for treatment. The biological function of these cells involves rapid proliferation within the bone marrow, secretion of monoclonal immunoglobulins, and the suppression of normal hematopoiesis. Therapeutic strategies targeting these cells include chimeric antigen receptor (CAR) T-cell therapies, bispecific T-cell engagers (BiTEs), and antibody-drug conjugates (ADCs). By binding to these specific antigens, drugs can direct the immune system to selectively eliminate the malignant cell population while sparing most healthy cells.

Other names

Myeloma-associated antigen-expressing cellsMultiple myeloma cellsMalignant plasma cellsBCMA-expressing cellsGPRC5D-expressing cells

Targeted cytolysis via T-cell redirection, antibody-dependent cellular cytotoxicity (ADCC), and intracellular delivery of cytotoxic payloads.